Print page |
E-mail page
| 
Download PDF
|
Add to briefcase
« Previous Release | Next Release »
San Diego, CA, October 24, 2005 - Cytori Therapeutics, Inc. (Frankfurt: XMP), today presented research results from two studies demonstrating that adipose stem and regenerative cells have an ability to form blood vessels and improve blood flow. In an in vivo preclinical study, adipose stem and regenerative cells restored blood flow to severely injured hind limbs. A second study showed that these cells spontaneously form capillary networks in vitro. The data from both studies were presented at the 8th Annual Tissue Engineering Society International Conference and Exhibition in Shanghai, P.R. China.
"These results are consistent with our previously published data which strongly suggest that adipose stem and regenerative cells contribute to repair and healing through their ability to form new blood vessels and improve the blood flow in existing vessels supplying injured tissues," stated Marc H. Hedrick, M.D., President for Cytori Therapeutics. "Our findings consistently demonstrate the potential of these cells in the treatment of cardiovascular disease, including heart attacks, congestive heart failure and peripheral vascular disease."
In an oral presentation, Cytori reported that adipose stem and regenerative cells injected intravenously into mice improved blood flow and rescued hind limbs two weeks after the femoral artery, the main artery supplying blood to the lower extremities, was surgically severed. In the in vitro study, Cytori found that after three weeks, adipose stem and regenerative cells spontaneously formed capillary networks without the use of growth factors traditionally required to coax cells into forming blood vessels. Additionally, the cells expressed proteins that are consistent with those known to contribute to blood vessel growth.
About Cytori Therapeutics
Cytori Therapeutics (Frankfurt: XMP) is discovering and developing proprietary cell-based therapeutics utilizing adult stem cells derived from adipose, also known as fat tissue. The Company's preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem cells, Cytori is developing its proprietary Celution™ system to isolate and concentrate a patient's own stem cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients.
Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking statements regarding events and trends which may affect Cytori Therapeutics' future operating results and financial position. Such statements are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially. Some of these risks and uncertainties are described (under the heading "Risk Factors") in Cytori Therapeutics' 2004 Form 10-K annual report for the year ended December 31, 2004 and subsequent SEC filings, which are available through the Company's web site. Cytori Therapeutics assumes no responsibility to update any revision of forward-looking statements to reflect events, trends or circumstances after the date they are made.
Contacts:
Tom Baker
Media/U.S. Investors
Tel. +1-858-458-0900
tbaker@cytoritx.com
Stefanie Bacher
International Investors
Tel. +1-858-458-0900
sbacher@cytoritx.com